Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
7.06
+0.09 (1.36%)
At close: May 9, 2025, 4:00 PM
7.38
+0.33 (4.61%)
After-hours: May 9, 2025, 7:49 PM EDT
Seres Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
103
Market Cap
61.51M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MCRB News
- 3 days ago - Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 11 days ago - Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - GlobeNewsWire
- 17 days ago - Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - GlobeNewsWire
- 2 months ago - Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 - GlobeNewsWire
- 2 months ago - Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach - GlobeNewsWire